We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Homogeneous ADCs Bearing Two Different Payloads Show Strong Synergy In Tumor Killing
Poster

Homogeneous ADCs Bearing Two Different Payloads Show Strong Synergy In Tumor Killing

Homogeneous ADCs Bearing Two Different Payloads Show Strong Synergy In Tumor Killing
Poster

Homogeneous ADCs Bearing Two Different Payloads Show Strong Synergy In Tumor Killing

Using engineered microbial transglutaminase (mTGase), we are able to conjugate any given toxin with an amine group to any mAB without the need of antibody re-engineering. Such a simple and quick site-specific conjugation method has enabled us to screen out endosome escaping & non-cleavable (EENC) linkers. These EENC linkers need an optimal length to achieve the highest ADC activity. ADCs made with EENC linkers are highly stable in human, rat and mouse plasma and potent. When two different payload toxins were conjugated site-specifically to one mAB molecule, the homogeneous hybrid ADC (DAR 2) prepared shows synergy towards tumor cell killing while mixtures of the respective two homogeneous ADCs (DAR 2) bearing the same toxins do not. The pM Ic50 in assay and high in-vivo potency challenges the widely accepted ADC concept of an activation pathway via lysosomal destruction to release free toxin. On the contrary, our data imply that ADC can be directly active after escaping from an endosome and as a result of multiple interactions of the different payloads, make the new ADCs more potent.
Advertisement